Concepedia

Publication | Open Access

A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study

DOIFull Paper Access

147

Citations

27

References

2021

Year

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint, Shengjie Wu, Azra H. Ligon, Neal I. Lindeman, Olivia Campagne, Anu Banerjee, Sridharan Gururangan, Lindsay Kilburn,
Neuro-Oncology

Abstract

Selumetinib was tolerable and led to responses and prolonged disease stability in children with recurrent/progressive OPHGs based upon radiographic response, PFS, and visual outcomes.

References

YearCitations

Page 1